

## Translation

### Supply Plan of "Tamiflu®" Anti-influenza Drug for the 2014-2015 Season

October 29, 2014 (Tokyo) - Chugai Pharmaceutical Co., Ltd. (hereafter, "Chugai") [Head office: Chuo-ku, Tokyo; Chairman & CEO: Osamu Nagayama] announced today that a supply plan of the anti-influenza drug "Tamiflu® Capsule 75" and "Tamiflu® Dry Syrup 3%" (generic name: oseltamivir phosphate) (hereafter, Tamiflu®) imported from F. Hoffmann-La Roche Ltd. [Head Office: Basel, Switzerland. CEO: Severin Schwan] for the 2014-2015 season (hereafter, this season) for Japan has been prepared.

Supply plan for this season (as of October 29, 2014)

Tamiflu® Capsule 75:	about 4.0 million treatment courses
Tamiflu® Dry Syrup 3%:	about 3.0 million treatment courses
Total:	about 7.0 million treatment courses

In addition, Chugai will consider additional supply of Tamiflu® depending on the situation of the epidemic of influenza.

Chugai will be very prepared for the supply of Tamiflu® in case of an epidemic of this seasonal influenza.

Tamiflu® is trademark of F. Hoffmann-La Roche Ltd., Basel, Switzerland.